This page contains guidance issued by the GMMMG High Cost Drugs Subgroup. If you are an NHS healthcare professional working within the GM region and wish to submit information for consideration by the group please contact the professional secretary of the group via email

Document Title Issue Date Review Date Status
GMMMG PBR Ex Devices 2020-21 20200608 Jun 2020 20210408 Apr 2021
GMMMG PBR Ex Drugs 2020-21 20200608 Jun 2020 20210408 Apr 2021
GM CCG commissioned high cost drugs management in the context of the COVID-19 pandemic 20200408 Apr 2020
Teriparatide biosimilar uptake recommendation 20191108 Nov 2019 To be reviewed if national or GMMMG guidance changes
Botulinum toxin guidance 20200108 Jan 2020 20220108 Jan 2022
GMMMG PBR Exclusions supporting information 20-21 20201008 Oct 2020 20211008 Oct 2021
Best Value Adalimumab Decision and Uptake Recommendation 20181208 Dec 2018
Free of charge (FOC) medicines schemes 20200108 Jan 2020 20220108 Jan 2022
Enabled Blueteq List 20210908 Sep 2021 updated monthly
Commissioning framework for biologic medicines: defining best value 20180608 Jun 2018 To be reviewed if national or GMMMG guidance changes
Position Statement for funding of High Cost Drugs when patients transition from Children or adolescent services to adult services 20171008 Oct 2017 To be reviewed if national or GMMMG guidance changes
Position statement for using biologic therapies to treat adult patients with Juvenile Idiopathic Arthritis (JIA) 20171008 Oct 2017 To be reviewed if national or GMMMG guidance changes
Implementation and principles of a Greater Manchester biosimilar gainshare agreement 20170708 Jul 2017 To be reviewed if national or GMMMG guidance changes
Rituximab Biosimilar Uptake Recommendation 20170608 Jun 2017 To be reviewed if national or GMMMG guidance changes
Prescribing of high cost biosimilar biological medicines 20160708 Jul 2016 To be reviewed if national or GMMMG guidance changes